SAB Biotherapeutics, Inc. (SABS) announced that the U.S. FDA granted Fast Track designation to SAB-142, an immunotherapy being developed for people with new-onset Stage 3 type 1 diabetes (T1D).
SAB-142 is being evaluated in the registrational Phase 2b SAFEGUARD study in people within 100 days of diagnosis; enrollment is expected to be completed in Q4 2026, with topline data anticipated in 2H 2027. An investigator-led Phase 3 study, PRISE-hATG, is designed to evaluate SAB-142 in people with Stage 3 T1D from 100 days to two years following diagnosis.
SAB Biotherapeutics, Inc. (SABS) reported that Chief Medical Officer Alexandra Kropotova had 473 shares of common stock withheld on September 17, 2026 to satisfy tax withholding requirements upon vesting of restricted stock units. After this tax-withholding disposition, she holds 41,853 shares directly, including vested and unvested RSU-related shares.
Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. report beneficial ownership of SAB Biotherapeutics, Inc. common stock. The Master Fund directly holds 6,627,501 shares of common stock, representing 7.3% of the class based on 90,986,368 shares outstanding as of August 3, 2026.
Perceptive Advisors, as investment manager, and Mr. Edelman, as managing member of Perceptive Advisors, may each be deemed to beneficially own these shares. All 6,627,501 shares are reported with shared voting and shared dispositive power; no reporting person has sole voting or sole dispositive power.
Caligan Partners LP and David Johnson filed an amended Schedule 13G reporting their beneficial ownership of common stock of SAB Biotherapeutics, Inc. Caligan, as investment manager to certain funds and accounts, and Johnson, as its managing partner, are the reporting persons.
They report beneficial ownership of 7,967,207 shares of SAB Biotherapeutics common stock, representing 8.8% of the class, based on 90,986,368 shares outstanding as of August 3, 2026. All reported shares are held with shared voting and dispositive power; neither reporting person has sole voting or sole dispositive power over these shares.
The filing notes that other persons (the underlying funds and accounts) may have rights to receive dividends or proceeds from the sale of these securities in accordance with the investment structure referenced in Item 2(a). David Johnson signs the report both in his capacity as managing partner of Caligan and in his individual capacity.
Commodore Capital and related filers report a significant ownership position in SAB Biotherapeutics, Inc. As of June 30, 2026, they may be deemed to beneficially own 8,948,170 shares of common stock, representing 9.9% of the class. This position includes 2,870,000 common shares, 5,946,400 shares issuable upon conversion of Series B Preferred Stock, and 131,770 shares issuable upon conversion of Series B Preferred Stock underlying Tranche 1 Warrants. Additional Tranche 1 and Tranche 2 Warrants are contractually limited by a 9.99% Beneficial Ownership Limitation, so those excluded securities are not counted in the reported stake.
SAB Biotherapeutics, Inc. received an amended Schedule 13G indicating that Vivo Opportunity Fund Holdings, L.P. and its general partner Vivo Opportunity, LLC may be deemed to beneficially own 22,637,108 shares of common stock and equivalents, while Vivo Opportunity Cayman Fund, L.P. and its general partner Vivo Opportunity Cayman, LLC may be deemed to beneficially own 2,286,301 shares.
These positions include existing common shares plus shares issuable upon conversion of Series B Preferred Stock and upon exercise of related Enrollment Warrants and Data Release Warrants that are exercisable or convertible within 60 days. Each reporting person reports beneficial ownership of 9.99% of the common stock class, with blocking provisions in the preferred stock and warrants that prevent conversions or exercises which would increase ownership above 9.99% of the issuer’s voting securities.
Woodline Partners LP filed an amended Schedule 13G reporting beneficial ownership of 5,455,355 shares of SAB Biotherapeutics, Inc. common stock, including shares issuable upon conversion of preferred stock underlying warrants. This represents 6.8% of the outstanding common stock.
The position consists of 1,180,355 common shares, plus 2,850,000 shares issuable from Series B Preferred Stock underlying Enrollment Warrants and 1,425,000 shares issuable from Series B Preferred Stock underlying Data Release Warrants, all held for Woodline Master Fund LP. The percentage is based on 76,464,094 common shares outstanding as of May 6, 2026. Woodline reports sole voting and dispositive power over the 5,455,355 shares, with the Woodline Fund entitled to dividends and sale proceeds.
Balyasny Asset Management and related entities reported significant ownership in SAB Biotherapeutics, Inc. common stock. Through Atlas Diversified Master Fund, Ltd. and Atlas Private Holdings (Cayman) Ltd., they beneficially own 7,225,439 shares, including 3,465,000 shares issuable upon exercise of 34,650 warrants.
This position represents approximately 9.45% of SAB Biotherapeutics’ 76,464,094 shares outstanding as of May 6, 2026. The warrants are subject to a Beneficial Ownership Limitation that blocks exercises which would result in ownership above 9.99% of outstanding shares.
Adage Capital Management, L.P. and related entities and individuals report beneficial ownership of 6,405,553 shares of SAB Biotherapeutics, Inc. common stock. This represents 8.38% of the company’s outstanding common stock, based on 76,464,094 shares outstanding as of May 6, 2026.
The reporting persons have shared voting and dispositive power over all 6,405,553 shares and no sole voting or dispositive power. The shares are held directly by Adage Capital Partners, L.P., with Adage Capital Management, L.P. as investment manager and Robert Atchinson and Phillip Gross reporting through their managing member roles in related entities.
RA Capital Management, L.P. and affiliated reporting persons report beneficial ownership of 9,609,852 shares of SAB Biotherapeutics, Inc. common stock, representing 9.9% of the class based on 90,986,368 shares outstanding as of August 3, 2026. This amendment reflects a change in ownership percentage due to an increase in SAB’s outstanding shares, not any new acquisitions or dispositions by the group.
The RA Capital Healthcare Fund directly holds 4,401,500 common shares, Series B preferred stock convertible into up to 12,738,500 common shares, preferred stock purchase warrants, and pre-funded warrants exercisable for up to 2,753,246 common shares. A Beneficial Ownership Blocker currently limits the fund and its affiliates from beneficially owning more than 9,609,852 common shares, with a default cap of 9.99%, adjustable up to 19.99% on 61 days’ notice.